bullish
Concord Biotech's US$650m Lock-Up Expiry - Some Could Be Tempted to Book Multi-Bagger Gains
483 Views06 Feb 2024 05:16
Concord Biotech Ltd (658823Z IN) listed in India on 18th Aug 23. Coming up for six-month lockup expiry on 7th Feb 24 are the firm’s pre-IPO shareholders, along with a portion of its promoters’ stake.
Boomeranged on Tue, 28 May 2024 10:28
Ontario is looking to raise US$56m from selling a 3.4% stake in Concord Biotech. The deal has a floor price of INR1,320/share, at a 8.5% discount to the stock's last close. Ontario's remaining stake will be locked up for 90 days, and Citi is the sole bookrunner.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Concord Biotech Ltd (CONCORDB IN): Accelerated Growth Ahead; Recent Pullback Comforted Valuation11 Jun 2024
- Concord Biotech's US$650m Lock-Up Expiry - Some Could Be Tempted to Book Multi-Bagger Gains06 Feb 2024
- Concord Biotech Ltd (658823Z IN): Q2 EBITDA and PAT Triples on Operational Efficiencies01 Dec 2023
- Concord Biotech IPO Trading - Strong Subscription Rates, Peers Have Moved up Since Last Note17 Aug 2023
- Concord Biotech IPO - Peer Comparison & Valuation - Smaller in Scale but Wider in Margins04 Aug 2023
x